High-dose chemotherapy and PBPC autografting in indolent lymphomas: Evaluation of minimal residual disease and molecular follow-up.

被引：0
|
作者：
Corradini, P
Astolfi, M
Caracciolo, D
Bondesan, P
Voena, C
Vitolo, U
Cinque, F
Pileri, A
Tarella, C
机构：
[1] Az Osped S Giovanni Battista, Div Osped Ematol, Torino, Italy
[2] Univ Turin, Az Osped S Giovanni Battista, Div Ematol, Torino, Italy
来源：
BONE MARROW TRANSPLANTATION | 1998年 / 21卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
634
引用
收藏
页码：S183 / S183
页数：1
相关论文
共 50 条
  • [21] Clinical implication of residual MIBG-positive disease in the follow-up of high-risk neuroblastoma treated with tandem high-dose chemotherapy and autologous stem cell transplantation
    Seo, Eun Seop
    Shin, Muheon
    Lim, Hana
    Cho, Hee Won
    Ju, Hee Young
    Cho, Young-Seok
    Yoo, Keon Hee
    Koo, Hong Hoe
    Lee, Ji Won
    Sung, Ki Woong
    PEDIATRIC BLOOD & CANCER, 2022, 69 (07)
  • [22] Extended Chemotherapy for Residual Disease after Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation in High Risk Neuroblastoma
    Park, H. J.
    Choi, J. Y.
    Kang, H. J.
    Kim, B. K.
    Hong, K. T.
    Kim, H. -Y.
    Park, S. -H.
    Cheon, J. -E.
    Kim, I. H.
    Cheon, G. J.
    Shin, H. Y.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S266 - S266
  • [23] Allogeneic cell-mediated immunotherapy at the stage of minimal residual disease following high-dose chemotherapy supported by autologous stem cell transplantation
    Slavin, S
    ACTA HAEMATOLOGICA, 2005, 114 (04) : 214 - 220
  • [24] Monitoring of minimal residual cancer in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy
    Drageset, V
    Nesland, JM
    Erikstein, B
    Skovlund, E
    Sommer, H
    Anker, G
    Wist, E
    Lundgren, S
    Bergh, J
    Kvalheim, G
    BREAST CANCER RESEARCH, 2005, 7 (Suppl 2) : S56 - S57
  • [25] Monitoring of minimal residual cancer in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy
    V Drageset
    JM Nesland
    B Erikstein
    E Skovlund
    H Sommer
    G Anker
    E Wist
    S Lundgren
    J Bergh
    G Kvalheim
    Breast Cancer Research, 7
  • [26] Very long-term molecular follow-up of minimal residual disease in patients with neuroblastoma
    Tchirkov, Andrei
    Greze, Victoria
    Plantaz, Dominique
    Rouel, Nadege
    Vago, Philippe
    Kanold, Justyna
    PEDIATRIC BLOOD & CANCER, 2018, 65 (12)
  • [27] Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma
    Nahi, Hareth
    Afram, Gabriel
    Uttervall, Katarina
    Lockmer, Sandra
    Tatting, Love
    Gahrton, Gosta
    Kashif, Muhammad
    Alici, Evren
    Stromberg, Olga
    Klimkowska, Monika
    Lund, Johan
    CANCER MEDICINE, 2023, 12 (22): : 20736 - 20744
  • [28] Post-transplant consolidation chemotherapy to eliminate minimal residual disease in myeloma patients after high-dose melphalan and autotransplantation: Feasibility and tolerance.
    Powles, R
    Sirohi, B
    Treleaven, J
    Kulkarni, S
    Bhagwati, N
    Saso, R
    Horton, C
    Singhal, S
    Mehta, J
    BLOOD, 1999, 94 (10) : 314B - 314B
  • [29] Long-term follow-up of high-dose chemotherapy followed by autologous stem cell transplantation in peripheral T-cell lymphomas at diagnosis.
    Cortelazzo, S
    Tarella, C
    Dodero, A
    Gianni, AM
    Francesco, Z
    Zanni, M
    Rambaldi, A
    Barbui, T
    Corradini, P
    BLOOD, 2004, 104 (11) : 260A - 260A
  • [30] Chemotherapy for osteosarcoma without high-dose methotrexate: A 12-year follow-up on 53 patients
    Tunn, Per-Ulf
    Reichardt, Peter
    ONKOLOGIE, 2007, 30 (05): : 228 - 232
12345